Nasdaq Copenhagen A/S: Pharma Equity Group A/S - admittance to trading and official listing of new shares due to a directed issue

The share capital of Pharma Equity Group A/S has been increased. The admittance
to trading and official listing of new shares will take effect as per 16
October 2024 in the ISIN below. 



ISIN          DK0061155009               
----------------------------------------------------------------
Name:         Pharma Equity Group           
----------------------------------------------------------------
Volume before change: 1,022,963,883 shares (DKK 102,296,388.30)
----------------------------------------------------------------
Change:        204,592,776 shares (DKK 20,459,277.60)  
----------------------------------------------------------------
Volume after change:  1,227,556,659 shares (DKK 122,755,665.90)
----------------------------------------------------------------
Subscription price   DKK 0.25                 
----------------------------------------------------------------
Face value:      DKK 0.10                 
----------------------------------------------------------------
Short name:      PEG                   
----------------------------------------------------------------
Orderbook ID:     21613                  
----------------------------------------------------------------





For further information, please contact: Surveillance, tel. +45 33 93 33 66

6 Richtige für 2025

Das Börsenjahr 2025 klopft schon an die Tür – und wie immer geht es um die Frage: Welche Aktien werden die großen Gewinner sein? Die Auswahl an Möglichkeiten ist riesig, doch nur ein paar echte Volltreffer stechen heraus.

Ob stabiler Dividenden-Lieferant, Tech-Pionier oder spekulative Wette im Krypto-Bereich – wir haben die Märkte für Sie ausgiebig durchforstet und präsentieren Ihnen 6 Unternehmen, die große Chancen auf außergewöhnliche Kurssteigerungen besitzen. Hier sind, speziell für Sie, Ihre „6 Richtigen“ für 2025.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche Unternehmen das Potenzial besitzen, im kommenden Jahr richtig durchzustarten!

Hier klicken

Zeit	Aktuelle Nachrichten
13.12.	Pharma Equity Group A/S: The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.	The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S. December 13, 2024Announcement No. 32 Pharma Equity Group... ► Artikel lesen
29.11.	Martin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/S
15.11.	Pharma Equity Group A/S: Consolidated Interim report 1 January - 30 September 2024	Consolidated Interim report 1 January - 30 September 2024 Company announcement no. 30 - November 15, 2024 Key points from the Q1-Q3-2024 report (period 1 January - 30 September 2024) On 15 November... ► Artikel lesen
23.10.	Pharma Equity Group A/S: Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.	Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051. October 23, 2024Company Announcement... ► Artikel lesen
14.10.	Major shareholder announcement - Pharma Equity Group A/S

Zeit

Aktuelle Nachrichten

13.12.

Pharma Equity Group A/S: The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.

The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S. December 13, 2024Announcement No. 32 Pharma Equity Group...
► Artikel lesen

29.11.

Martin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/S

15.11.

Pharma Equity Group A/S: Consolidated Interim report 1 January - 30 September 2024

Consolidated Interim report 1 January - 30 September 2024 Company announcement no. 30 - November 15, 2024 Key points from the Q1-Q3-2024 report (period 1 January - 30 September 2024) On 15 November...
► Artikel lesen

23.10.

Pharma Equity Group A/S: Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051. October 23, 2024Company Announcement...
► Artikel lesen

14.10.

Major shareholder announcement - Pharma Equity Group A/S

	Indizes	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Aktien	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Xetra-Orderbuch


	Fonds	Kurs	%


	Devisen	Kurs	%


	Rohstoffe	Kurs	%


	Themen	Kurs	%



Erweiterte Suche

PHARMA EQUITY GROUP A/S

Nasdaq Copenhagen A/S: Pharma Equity Group A/S - admittance to trading and official listing of new shares due to a directed issue